JP2005509597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509597A5 JP2005509597A5 JP2003519439A JP2003519439A JP2005509597A5 JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5 JP 2003519439 A JP2003519439 A JP 2003519439A JP 2003519439 A JP2003519439 A JP 2003519439A JP 2005509597 A5 JP2005509597 A5 JP 2005509597A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- 1racp
- composition according
- receptor
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 7
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 7
- 102000019223 Interleukin-1 receptor Human genes 0.000 claims 6
- 108050006617 Interleukin-1 receptor Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 2
- -1 IFNγ Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000011280 coal tar Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960001330 hydroxycarbamide Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 235000005282 vitamin D3 Nutrition 0.000 claims 1
- 239000011647 vitamin D3 Substances 0.000 claims 1
- 229940021056 vitamin d3 Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31078901P | 2001-08-07 | 2001-08-07 | |
| PCT/US2002/024948 WO2003014309A2 (en) | 2001-08-07 | 2002-08-07 | Interleukin-1 receptors in the treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509597A JP2005509597A (ja) | 2005-04-14 |
| JP2005509597A5 true JP2005509597A5 (https=) | 2006-01-05 |
Family
ID=23204113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003519439A Pending JP2005509597A (ja) | 2001-08-07 | 2002-08-07 | 疾患の治療におけるインターロイキン−１受容体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030049255A1 (https=) |
| EP (1) | EP1450837A4 (https=) |
| JP (1) | JP2005509597A (https=) |
| AU (1) | AU2002324625B2 (https=) |
| CA (1) | CA2456762A1 (https=) |
| MX (1) | MXPA04001187A (https=) |
| PL (1) | PL374118A1 (https=) |
| WO (1) | WO2003014309A2 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU740405B2 (en) * | 1998-05-15 | 2001-11-01 | Genentech Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7771719B1 (en) * | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20030203451A1 (en) * | 2000-08-24 | 2003-10-30 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US7718397B2 (en) * | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| US20030180255A1 (en) * | 2000-08-24 | 2003-09-25 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20090035261A1 (en) * | 2000-03-21 | 2009-02-05 | Jian Chen | IL-17 homologous polypeptides and therapeutic uses thereof |
| US20030096969A1 (en) * | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP2784084B2 (en) | 2003-07-08 | 2023-10-04 | Novartis Pharma AG | Antagonist antibodies to IL-17A/F heterologous polypeptides |
| AR046583A1 (es) * | 2003-11-14 | 2005-12-14 | Ucl Biomedica Plc | Uso de una composicion inmunomoduladora |
| HUE026260T2 (en) | 2003-11-21 | 2016-06-28 | Ucb Biopharma Sprl | A method for treating multiple sclerosis by inhibiting IL-17 activity |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1751175B1 (en) * | 2004-05-05 | 2012-07-25 | VALORISATION-RECHERCHE, Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| WO2007004060A2 (en) * | 2005-05-05 | 2007-01-11 | Valorisation Hsj, Societe En Commandite | Cytokine receptor modulators and uses thereof |
| PL1940465T3 (pl) | 2005-10-26 | 2013-01-31 | Novartis Ag | Nowe zastosowanie przeciwciał anty-IL-1beta |
| US7504106B2 (en) * | 2006-03-14 | 2009-03-17 | Boris Skurkovich | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis |
| JP2009183176A (ja) * | 2008-02-05 | 2009-08-20 | Univ Of Tokyo | Ｉｌ−１タイプｉｉレセプター遺伝子の欠損変異体マウス |
| RU2474588C2 (ru) | 2008-05-05 | 2013-02-10 | Новиммун Са | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения |
| CA2725143A1 (en) * | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
| CN102458437B (zh) | 2009-05-05 | 2015-06-10 | 诺维莫尼公司 | 抗il-17f抗体及其使用方法 |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| EP2582391B1 (en) | 2010-06-18 | 2018-10-03 | XBiotech, Inc | Arthritis treatment |
| US9403906B2 (en) | 2011-01-19 | 2016-08-02 | Cantargia Ab | Method of treatment of a solid tumor with interleukin-1 accessory protein antibody |
| US9724409B2 (en) * | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| WO2014090800A1 (en) | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
| JP7114460B2 (ja) * | 2015-06-26 | 2022-08-08 | サノフィ・バイオテクノロジー | モノクローナル抗ＩＬ－１ＲＡｃＰ抗体 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US11633425B2 (en) | 2021-05-13 | 2023-04-25 | Ahava—Dead Sea Laboratories Ltd. | Anti-glycation compositions |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| US20260015427A1 (en) | 2024-06-25 | 2026-01-15 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989004838A1 (en) * | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5350683A (en) * | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| WO1991018982A1 (en) * | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| ATE242322T1 (de) * | 1992-03-30 | 2003-06-15 | Immunex Corp | Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält |
| PE64396A1 (es) * | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| NZ322197A (en) * | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| US5965583A (en) * | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| EP1712239A3 (en) * | 2000-05-12 | 2007-08-22 | Immunex Corporation | Interleukin-1 inhibitors in the treatment of diseases |
| WO2002064630A2 (en) * | 2000-10-31 | 2002-08-22 | Immunex Corporation | Il-1 receptor accessory protein |
-
2002
- 2002-08-07 US US10/215,211 patent/US20030049255A1/en not_active Abandoned
- 2002-08-07 EP EP02759279A patent/EP1450837A4/en not_active Withdrawn
- 2002-08-07 PL PL02374118A patent/PL374118A1/xx not_active Application Discontinuation
- 2002-08-07 JP JP2003519439A patent/JP2005509597A/ja active Pending
- 2002-08-07 AU AU2002324625A patent/AU2002324625B2/en not_active Ceased
- 2002-08-07 WO PCT/US2002/024948 patent/WO2003014309A2/en not_active Ceased
- 2002-08-07 CA CA002456762A patent/CA2456762A1/en not_active Abandoned
- 2002-08-07 MX MXPA04001187A patent/MXPA04001187A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509597A5 (https=) | ||
| McCulloch et al. | Signalling platforms that modulate the inflammatory response: new targets for drug development | |
| Vane et al. | Inflammation and the mechanism of action of anti‐inflammatory drugs | |
| ES2659205T3 (es) | Uso de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il)piperidin-2,6-diona en el tratamiento de enfermedades inflamatorias y relacionadas con el sistema inmune | |
| Busson | Update on ibuprofen | |
| US4871733A (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
| CA1292694C (en) | Inhibition of interleukin-1 by monocytes and/or macrophages | |
| Crowson et al. | Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management | |
| CN100519554C (zh) | 用於治疗爱滋病之ccr5拮抗剂 | |
| TW449473B (en) | Compositions for inhibition of the pathophysiologic actions in mammals of tumor necrosis factor-alpha | |
| Sihra et al. | Effect of cyclosporin A on the allergen-induced late asthmatic reaction. | |
| JP2005533005A5 (https=) | ||
| JP2024094370A (ja) | ＣＣケモカイン受容体９（ＣＣＲ９）の阻害剤と抗α４β７インテグリン遮断抗体の併用療法 | |
| WO2004082715A1 (ja) | 炎症性腸疾患治療剤としての併用医薬 | |
| JP2003512429A (ja) | デスロラタジンを用いた睡眠障害処置 | |
| WO2003014309A2 (en) | Interleukin-1 receptors in the treatment of diseases | |
| AU2002324625A1 (en) | Interleukin-1 receptors in the treatment of diseases | |
| JP2006515299A5 (https=) | ||
| Kudlacz et al. | Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule α4β1 antagonists | |
| Johnson | Neoplastic fever | |
| JP2005526053A5 (https=) | ||
| JP2002501039A (ja) | Ｖｌａ−４アンタゴニスト | |
| US20030176316A1 (en) | Methods for treatment of rheumatoid arthritis | |
| JP4139453B2 (ja) | 細胞接着阻害剤 | |
| JP2009523803A (ja) | トリアゾール化合物による炎症性疾患の処置 |